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Oxidative stress is generally considered as the consequence of an imbalance between
pro- and antioxidants species, which often results into indiscriminate and global damage
at the organismal level. Elderly people are more susceptible to oxidative stress and
this depends, almost in part, from a decreased performance of their endogenous
antioxidant system. As many studies reported an inverse correlation between systemic
levels of antioxidants and several diseases, primarily cardiovascular diseases, but also
diabetes and neurological disorders, antioxidant supplementation has been foreseen as
an effective preventive and therapeutic intervention for aging-associated pathologies.
However, the expectations of this therapeutic approach have often been partially
disappointed by clinical trials. The interplay of both endogenous and exogenous
antioxidants with the systemic redox system is very complex and represents an issue
that is still under debate. In this review a selection of recent clinical studies concerning
antioxidants supplementation and the evaluation of their influence in aging-related
diseases is analyzed. The controversial outcomes of antioxidants supplementation
therapies, which might partially depend from an underestimation of the patient specific
metabolic demand and genetic background, are presented.
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INTRODUCTION
Reactive oxygen species (ROS) comprise both free radicals such as superoxide (O•−2 ), and non-
radical species such as hydrogen peroxide (H2O2), (Weseler and Bast, 2010; Gülçin, 2012). These
molecules, continuously produced in the cell, are involved in physiological events such as cell
differentiation, primary immune defense, and signaling (Poli et al., 2004; Shah and Sauer, 2006;
Gülçin, 2012). Indeed, some ROS such as H2O2 are versatile players of the molecular signaling
machinery because they are small, highly diffusible, and can be rapidly generated and degraded
(Gough and Cotter, 2011).
Both radical and non-radical ROS are pro-oxidant species capable of oxidizing in the cell
different biomolecules (Sies, 1991), which leads to a sequence of chain reactions that may end up
in molecular and cellular damage (Gülçin, 2012).
The balance between beneficial and detrimental effects of ROS is preserved in the cell by the
activity of a complex array of non-enzymatic and enzymatic detoxification mechanisms collectively
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known as antioxidants (Sies, 1993; Bast and Haenen, 2015).
Antioxidants are able to counteract, at relatively low
concentrations, the damage induced in cells by ROS, thus
protecting physiological targets such as lipids, DNA and proteins
(Loguercio et al., 2012; Bast and Haenen, 2015). Noteworthy,
antioxidants may also act indirectly by regulating redox-sensitive
signal transduction pathways including transcription factors, and
inhibition of poly (ADP-ribose) polymerase (PARP-1) (Weseler
and Bast, 2010).
An imbalance of either the pro-oxidant and/or the antioxidant
parties is at the origin of a complex physiological status known
as “oxidative stress” (Davies, 1995; Conti et al., 2015a,b), which
may be also favored by external sources, and by the presence
of dietary compounds of pro-oxidant nature such as quinones
(Gülçin, 2012).
Elderly people are more susceptible to oxidative stress
due to a reduction in the efficiency of their endogenous
antioxidant systems. Organs such as heart and brain,
with limited replication rate and high levels of oxygen
consumption, are particularly vulnerable to this phenomenon,
thus explaining almost in part the high prevalence of
neurological and cardiovascular diseases (CVD) in elderly
(Ames et al., 1993; Stadtman and Berlett, 1997; Corbi et al.,
2008).
A substantial body of literature reported an inverse correlation
between serum or plasma total antioxidant capacity and both
the onset and progression of several diseases, primarily CVD
(Ciancarelli et al., 2012), but also diabetes (Opara et al., 1999),
respiratory (Gumral et al., 2009) and neurological disorders
(Schrag et al., 2013).
Consequently, antioxidants supplementation was suggested
as a promising therapy in line with the general acceptance
of the Free Radical Theory of Aging (FRTA) (Harman, 1956,
2006). First presented in Harman (1956), this theory is based
on the assumption that lowering the global level of ROS in
the body might retard aging, increase life span and be effective
in preventing and treating aging-associated diseases (Sadowska-
Bartosz and Bartosz, 2014). Further refinements of this theory
addressed the roles of other activated oxygen species in aging in
the more generalized Oxidative Stress Theory of Aging (OSTA)
(Bokov et al., 2004; Muller et al., 2007).
This awareness resulted from one side in boosting in the
scientific community the quest for novel natural or synthetic
antioxidants (Donadio et al., 2015), and on the other in
establishing several treatment strategies whose aim was to
counterbalance oxidative stress by supplementing exogenous
antioxidants, either singularly or in combination (Bouayed and
Bohn, 2010).
However, the clinical expectations of antioxidants-based
therapies have been frequently disappointed. The interplay
between endogenous and exogenous antioxidants with the
overall redox system in humans is very complex and represents
a topical issue that is still under debate in the scientific
community.
In this review a selection of recent clinical studies concerning
antioxidants supplementation and the evaluation of their
influence in aging-related diseases is analyzed (Table 1).
NATURAL ANTIOXIDANTS USED IN
RECENT CLINICAL STUDIES
Many natural compounds have been considered, either singularly
or in combination, for supplementation therapies. Among
them, we devoted particular attention to a specific subset of
molecules such as vitamin C, vitamin E, resveratrol, curcumin,
hydroxytyrosol and coenzyme Q10.
Ascorbic acid is the main form of vitamin C in the human
body and acts as the co-substrate for several enzymes that are
important for the organism’s functioning. Its antioxidant activity
relies on the ability to be reversibly oxidized to ascorbyl radical
and then to dehydroascorbate (DHA) (Wells and Xu, 1994).
The distribution and the concentration of vitamin C in
the organs depend on their specific ascorbate requirements
and on the tissue distribution of sodium-dependent vitamin C
transporter 1 and 2 (SVCT1 and SVCT2) (Figueroa-Mendez and
Rivas-Arancibia, 2015).
Vitamin C (ascorbic acid) has different important roles in
the cell; as a reducing agent and an antioxidant, ascorbate is
able to react and inactivate ROS and, most importantly, reduces
in membranes LDL and α-tocopheroxyl radicals to regenerate
α-tocopherol (Vitamin E) (Chambial et al., 2013).
One of the several biological functions mediated by ascorbate
is the enhancement of nitric oxide bioavailability, which is
essential to preserve endothelial homeostasis (Carr and Frei,
1999). A recent metanalysis (Ashor et al., 2014) revealed that
vitamin C supplementation counteracts endothelial dysfunction
(ED), which is doubtless one of the major contributors for both
the development and progression of CVDs (Versari et al., 2009;
Conti et al., 2012b, 2013; Corbi et al., 2012; Zhang et al., 2014),
suggesting a clinical impact of supplementation only in subjects
at higher CVDs risk. Antoniades et al. (2004) found that a
vitamin C supplementation of 2 g/day for 4 weeks increased
forearm vasodilator response to reactive hyperemia in patients
with combined diabetes (DM) and coronary artery diseases
(CAD).
An interesting study by Mullan et al. (2002) showed that an
oral administration of ascorbic acid (500 mg/day) for 1 month
lowered blood pressure and reduced systemic arterial stiffness;
conversely, other two randomized controlled trials failed to prove
a blood pressure-lowering effect of vitamin C supplementation
(Lovat et al., 1993; Ghosh et al., 1994).
However, the role played by vitamin C in aging-associated
diseases has not been adequately investigated in clinical trials
mainly because this antioxidant was often used in combination
with other molecules (Watanabe et al., 1998; Salonen et al., 2003).
When referring to vitamin E, a family of 8 isoforms classified
in two categories is considered: four saturated analogs (α, β,
γ, and δ) called tocopherols and four unsaturated analogs
indicated as tocotrienols, which differ for the methylation pattern
(Cardenas and Ghosh, 2013). These molecules are hydrophobic
fat-soluble compounds found in a variety of food sources such as
corn oil, peanuts, vegetable oils, fruits and vegetables (Cardenas
and Ghosh, 2013). Most of the studies presented in literature
have been performed using α-tocopherol (Wallert et al., 2014;
Hanson et al., 2015) that is considered the most active isomer
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TABLE 1 | Clinical studies performed with the main antioxidants.
Antioxidant Disease Primary results Reference
Vitamin C Type 2 DM and CAD ↑ Forearm vasodilator response Antoniades et al., 2004
DM ↓ Arterial blood pressure and improvement of arterial stiffness Mullan et al., 2004
IHD Prevention of nitrate tolerance Watanabe et al., 1998
Vitamin E CAD ↓ Rate of non-fatal MI Stephens et al., 1996
CVD and DM No effect on cardiovascular outcomes Yusuf et al., 2000
Vascular disease and DM ↑ Risk for HF Lonn et al., 2005
Prior MI ↑ Chronic HF in patients with LVD Marchioli et al., 2006
CAD ↓ Plasma biomarkers of oxidative stress and inflammation Devaraj et al., 2007
Resveratrol Hypertension and dyslipidemia ↓ Endothelial dysfunction Carrizzo et al., 2013
DM Improvement of glucose control and insulin sensitivity Liu et al., 2014
Coenzyme Q10 CAD ↑ Antioxidant enzymes activities and ↓inflammation Lee et al., 2013
Vitamin E and C Hypercholesterolemia ↓ atherosclerotic progression Salonen et al., 2003
Vitamins C, E and
β-carotene (alone
or in combination)
CVD No overall effects on cardiovascular events Cook et al., 2007
DM, diabetes mellitus; CAD, coronary artery disease; IHD, ischemic heart disease; CVD, cardiovascular disease; MI, myocardial infarction; HF, heart failure; LVD, left
ventricular dysfunction.
within this group and the main hydrophobic antioxidant in cell
membranes and circulating lipoproteins. Its antioxidant function
is strongly supported by the regeneration promoted by vitamin
C α-Tocopherol exhibits strong antioxidant capacity in vitro and
has been shown to inhibit LDL oxidation (Wallert et al., 2014).
In addition, α-tocopherol shows a remarkable anti-
inflammatory action by inhibiting, for example, cyclooxygenase-
2 (COX2) (O’Leary et al., 2004). Next to its antinflammatory
and antioxidative properties, vitamin E shows other properties,
such as the modulation of the expression of genes encoding
proteins involved in signaling (Cardenas and Ghosh, 2013). In
addition vitamin E is also involved in the uptake, transport and
degradation of tocopherols, as well as the uptake of lipoproteins
and the storage and export of lipids such as cholesterol (Cardenas
and Ghosh, 2013).
The beneficial effects of vitamin E dietary intake have been
described (O’Leary et al., 2004; Hanson et al., 2015), whereas
the data concerning vitamin E supplementation are controversial.
An old randomized controlled trial by Stephens et al. (1996)
showed that in patients with CAD, 1 year of α-tocopherol
supplementation reduced the rate of non-fatal myocardial
infarction. However, very few human studies have confirmed
the efficacy of vitamin E supplementation in aging-associated
diseases, and most of them focused on the role of vitamin E
supplementation in influencing aspects of aging phenotypes,
such as oxidative stress and inflammation biomarkers. In this
specific context some investigations, performed both in animals
models and in humans, effectively demonstrated benefits of
vitamin E supplementation (Iuliano et al., 2000; Navarro et al.,
2005; Abdala-Valencia et al., 2012), while others showed negative
impact (Bjelakovic et al., 2012), or no effect at all (Morley and
Trainor, 2001; Hemilä and Kaprio, 2011).
Two large randomized trials (Yusuf et al., 2000; Lonn et al.,
2005) investigated the impact of vitamin E supplementation
on CVDs and cardiovascular events in patients at high risk.
The “Heart Outcomes Prevention Evaluation (HOPE)” analyzed
the efficacy of a treatment with vitamin E in preventing
cardiovascular outcomes in 9,541 patients with CVD or diabetes
in addition to at least one other risk factor (Yusuf et al.,
2000). This study, with mean follow-up of 4.5 years, showed
that vitamin E did not reduce the incidence of cardiovascular
events when compared to placebo, thus suggesting the lack of an
evident beneficial effect exerted by this antioxidant (Yusuf et al.,
2000).
The “HOPE-TOO” (Lonn et al., 2005) an extension of the
HOPE study, was aimed at assessing whether longer duration of
the treatment with vitamin E could prevent cancer and/or CVD
during a follow-up of 7 years. The HOPE-TOO, involving 7,030
patients, confirmed that administration of 400 IU of vitamin
E had no evident impact either on cancer outcomes or on
major cardiovascular events and death. Furthermore, during the
HOPE-TOO study, the investigators advanced the hypothesis
that vitamin E supplementation might even be responsible to
increase the risk of heart failure (Lonn et al., 2005).
Another clinical trial explored the effect of vitamin E on
the development of chronic heart failure (CHF) in 8,415 post-
infarction patients without CHF at baseline (Marchioli et al.,
2006). The authors found that vitamin E treatment was associated
with a 50% increase of CHF in patients with left ventricular
dysfunction, thus confirming the conclusion raised by the HOPE
trial investigators.
More recently, Devaraj et al. (2007) evaluated the effect
of a high dose of α-tocopherol (1,200 IU/die for 2 years)
in CAD patients with high levels of oxidative stress. The
authors demonstrated that vitamin E supplementation lowered
plasmatic levels of inflammation markers, such as high-sensitivity
C-reactive protein and tumor necrosis factor-alpha, and the
levels of oxidative stress biomarkers, such as plasmatic oxidized
LDL, urinary F2-isoprostanes and monocytes superoxide anion
concentrations (Devaraj et al., 2007). However, α-tocopherol
supplementation failed to induce any change in intima-media
thickness of carotid arteries and no significant differences in
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cardiovascular events were observed between patients treated
with vitamin E and those with placebo (Devaraj et al.,
2007).
As previously underlined, vitamins E and C have been
frequently used in combination in clinical trials concerning
aging-associated diseases. The “Women’s antioxidant
Cardiovascular Study (WACS)” (Cook et al., 2007) investigated
the effect of vitamins C, E and β-carotene (alone or in
combination) in preventing cardiovascular events in 8,171
patients with either a history of CVD or at least three
cardiovascular risk factors, and during an average 9.4 year
follow-up (Cook et al., 2007). Results from WACS, as in the
case of other antioxidant trials performed with women, failed
to find any preventive effects of the antioxidants used on
CVD.
The Physicians’ Health Study II (PHS II) (Sesso et al., 2008)
randomized trial investigated instead the effects of vitamins E and
C in the prevention of CVD in men during a mean follow-up of
8 years. This trial did not evidence any benefit from antioxidant
supplementation on major CVD outcomes; moreover, vitamin
E was associated with an increased risk of stroke (Sesso et al.,
2008).
In a recent prospective study performed with 3,919 aged
men, Wannamethee et al. (2013) showed that higher plasma
levels of vitamin C, but not those of vitamin E, are inversely
associated with cardiovascular risk factors, including blood
lipids and blood pressure. Notably, whereas the dietary intake
of vitamin C did not exert any influence, the dietary intake
of vitamin E was significantly correlated with increased risk
of HF (Wannamethee et al., 2013). The authors of this
interesting investigation suggested that the reason for the
association between vitamin E intake and HF might depend
by the fact that vitamin E (α-tocopherol) may become a pro-
oxidant in an environment characterized by high oxidative
stress, such as an aged biological system (Wannamethee et al.,
2013).
Resveratrol (3, 4′, 5-trihydroxystilbene) is a phytoalexin
that belongs to the stilbene class of compounds, abundant
in many plants, such as peanuts, blueberries, pine nuts and
grapes where it mainly accumulates in a glycosylated form,
and that is synthesized in response to fungal infection and to
some environmental stresses like climate, ozone and ultraviolet
irradiation (Harikumar and Aggarwal, 2008).
Resveratrol appears to modulate numerous cell-signaling
pathways through the regulation of different molecular targets
including the AMP-regulated kinase AMPK and the NAD-
dependent deacetylase Sirt-1 (Yun et al., 2014; Conti et al.,
2015a). The variety of molecular mechanisms mediated by
this compound translates into a plethora of biological actions,
primarily, antioxidant and anti-inflammatory effects. Resveratrol
is a good antioxidant and blocks in vitro LDL oxidation, a
biological phenomenon associated with the risk of coronary
heart disease and myocardial infarction (Khurana et al., 2013).
In rodents, resveratrol supplementation has been shown to
decrease cardiovascular risk factor, including blood lipids and
VCAM-1, to improve cardiovascular function and physical
capacity and to decrease inflammation in the vasculature of aged
animals leading to improved vascular function (Gliemann et al.,
2013).
The anti-inflammatory properties of resveratrol have been
proved by several in vitro experiments. For instance, resveratrol
was showed to suppress NF-κB activity induced by beta-
amyloid in PC12 neuron cell lines, (Jang and Surh, 2003)
and to reduce the production of IL-1 beta and TNF-alpha
induced by LPS or beta-amyloid in the microglia (Capiralla
et al., 2012; Zhong et al., 2012), suggesting a neuroprotective
effect that has also been confirmed in cellular models of
neurodegenerative disorders, such as Parkinson’s and Alzheimer’s
diseases (Albani et al., 2009). Resveratrol anti-inflammatory effect
has been demonstrated also in vivo, i.e., in an animal model
of asthma in which this molecule mitigated structural airway
remodeling (Royce et al., 2011) or in rats with LPS-induce
liver failure where resveratrol improved hepatotoxic markers
by multiple mechanisms such as downregulation of NOS-2,
and modification of oxidative stress parameters (Farghali et al.,
2009).
Despite the promising results reported in vitro (Zhang et al.,
2011; Montesano et al., 2013) and in animal models (Saleh et al.,
2014), few studies have been performed directly in humans and
the results obtained are not quite convergent.
Recent studies underlined the importance of patient selection
in evaluating the potential therapeutic effects of resveratrol.
Recently, Carrizzo et al. (2013) conducted an ex vivo study
to investigate the effects of resveratrol on superior thyroid
artery obtained from 59 patients (63 years of mean age)
with hypertension and dyslipidemia, and found that resveratrol
reduced ED via modulation of NO metabolism and attenuation
of vascular oxidative stress. Interestingly, resveratrol failed to
exert any effect in vessels from patients without hypertension
or dyslipidemia (Carrizzo et al., 2013). A differential effect
of resveratrol influenced by the initial health status was also
suggested by a recent meta-analysis by Liu et al. (2014) which
highlighted that resveratrol improves glucose control and insulin
sensitivity in diabetic patients but does not affect glycemic values
in non-diabetic subjects.
In a recent work published by Gliemann et al. (2013), the
authors tested for the first time the combined effect of exercise
training (ET) and resveratrol on vascular function in aged
humans. In this trial 27 healthy physically inactive aged men
were randomized into 8 weeks of daily intake of either 250 mg of
trans-resveratrol or of placebo and were subjected to concomitant
high-intensity ET (Gliemann et al., 2013).
The main aim of the study was to confirm if oral
resveratrol supplementation improved the positive
cardiovascular adaptations to ET in aged subjects by
specifically increasing sirtuin 1 (SIRT1) mediated signaling
and by promoting the endogenous antioxidant system.
Interestingly, results showed that, whereas ET effectively
improved several cardiovascular health parameters in aged
men, concomitant resveratrol supplementation somehow
blunted most of these effects leading, among others, to a
significantly lower improvement in the training-induced
increase in maximal oxygen uptake (Gliemann et al.,
2013).
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Curcumin is a lipophilic bioactive phenol derived from the
rhizome of Curcuma longa, which shows low solubility and
stability in aqueous solution. It is contained in culinary curry
and used as a coloring agent in food (Bhullar et al., 2013). Orally
ingested curcumin is metabolized into the active metabolite
tetrahydrocurcumin by a reductase found in the intestinal
epithelium (Sadowska-Bartosz and Bartosz, 2014). Extensive
research during the last few decades has suggested a strong
therapeutic and pharmacological potential of this molecule as
antioxidant, antimutagenic, antiprotozoal and antibacterial agent
(Bhullar et al., 2013).
Curcumin strong medicinal properties are also associated
with reported anti-cancer and neuroprotective effect such
as in Alzheimer disease (Brondino et al., 2014). A hormetic
mechanism of action of this compound is suggested from
studies showing that expression levels of the stress response
protein Heme Oxygenase-1 (HO-1) were increased in cultured
hippocampal neurons treated with curcumin (Scapagnini
et al., 2006). Moreover, this phenolic compound has been
shown to reverse chronic stress-induced impairment of
hippocampal neurogenesis and increase expression of brain-
derived neurotrophic factor (BDNF) in an animal model of
depression (Xu et al., 2007). Several studies also showed that
curcumin interacts with NF-κB, and through this interaction
exerts protective function also in the regulation of T-cell-
mediated immunity (Kou et al., 2013). Recently González-Reyes
et al. (2013) identified curcumin as a neuroprotector against
hemin, the oxidized form of heme, which induced damage in
primary cultures of cerebellar granule neurons of rats. In this
study, a pretreatment of the neurons with 5–30 µM curcumin
increased by 2.3–4.9 fold HO-1 expression and by 5.6–14.3-fold
Glutathione (GSH) levels. Moreover, 15 µM curcumin lowered
by 55% the increase in ROS production, by 94% the reduction of
GSH/glutathione disulfide ratio, and by 49% cell death induced
by hemin. Furthermore, curcumin induced the translocation
into the nucleus of nuclear factor related factor-2 (Nrf2),
thereby stimulating an inflammatory and antioxidant response
against hemin-induced neuronal death (González-Reyes et al.,
2013).
Curcumin effects on both the arterial endothelial function and
the central arterial compliance was recently evaluated in post-
menopausal women that underwent a daily ingestion of 150 mg
of curcumin (Akazawa et al., 2012). In 32 post-menopausal
women the Flow Mediated Dilation (FMD) measured arterial
endothelial function, before and after 8 weeks of curcumin
ingestion or ET. After this time, the authors observed that
FMD increased significantly both in the exercise and curcumin
groups, whereas no significant change in FMD was detected
in the control group (Akazawa et al., 2012). The results
obtained suggested that a regular ingestion of curcumin could
improve endothelial function and might be a potential alternative
treatment for patients who are unable to exercise. In a different
study performed by the same group (Akazawa et al., 2013)
and involving this time 51 post-menopausal women, the effects
of curcumin ingestion alone and in combination with aerobic
ET on central arterial compliance were evaluated. In this case
also, the regular ingestion of curcumin, as the ET alone,
significantly increased carotid arterial compliance in the group
analyzed. Interestingly, the combination of ET and curcumin
ingestion, differently from what observed with resveratrol
(Gliemann et al., 2013), led to a cumulative beneficial effect in
the improvement of the arterial compliance (Akazawa et al.,
2013).
Hydroxytyrosol is an ortho-diphenol (a catechol) abundant in
olive, fruits and extra virgin olive oil (Waterman and Lockwood,
2007). This compound, due to its catecholic structure, shows a
marked antioxidant activity and is able to scavenge oxygen and
nitrogen free radicals, inhibit LDL oxidation, platelet aggregation
and endothelial cell activation, and protects DNA from oxidative
damage (Waterman and Lockwood, 2007; Notomista et al., 2011;
Bulotta et al., 2014). Hydroxytyrosol is also a metal chelator and is
able to scavenge the peroxyl radicals and break peroxidative chain
reactions producing very stable resonance structures (Bulotta
et al., 2014). Interestingly, scavenging activity of hydroxytyrosol
has also been demonstrated with respect to hypochlorous acid
(HOCl) (Visioli et al., 1998) a potent oxidant produced in vivo
at the site of inflammation, a phenomenon which may be critical
for the protection from atherosclerosis, since HOCl can oxidize
the apoproteic component of LDL. Moreover, it has been recently
reported (Giordano et al., 2014) that hydroxytyrosol is endowed
with the ability to modulate an adaptive signaling pathway
activated after endoplasmic reticulum (ER) stress and to improve
ER homeostasis itself.
The antioxidant activity of hydroxytyrosol seems to be related
in vivo to its high bioavailability: various studies have in fact
documented a high degree of absorption of this compound,
which is fundamental to exert its biological activities (Bulotta
et al., 2014). Several studies, mostly performed in cell and animal
models, have suggested beneficial effects of hydroxytyrosol in the
prevention or treatment of chronic and degenerative diseases,
especially CVD and cancer (Facchini et al., 2014). Most of the
studies currently presented in literature on hydroxytyrosol are
performed in vitro on cultured eukaryotic cells and very few are
the clinical trials performed in humans and more specifically
on elderly people. One of the main reasons is probably the
fact that purified hydroxytyrosol is still very expensive, which
hampers its use for long-lasting trials. Currently, the attention
of the scientific community is focused more on the effect of
olive oil supplementation on health, but olive oil is a complex
mixture containing variable amounts of triacylglycerols, fatty
acids and polyphenols (Waterman and Lockwood, 2007), thus no
conclusive hypothesis of the use of purified hydroxytyrosol can
yet be drawn from these studies.
Oliveras-López et al. (2013) evaluated the effects of daily
consumption of extra virgin olive oil in 62 subjects aged
65–96 years. After a 6-weeks daily intake of polyphenol-
rich olive oil with high oleuropein derivative contents, the
authors found a significant improvement in lipid profiles,
including a reduction of total cholesterol and a significant
increase of HDL levels. Moreover, in the same subjects, an
increase of serum total antioxidant capacity, and a concomitant
significant increase of catalase in erythrocytes and decrease in
superoxide dismutase and glutathione peroxidase activities were
also observed (Oliveras-López et al., 2013).
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Coenzyme Q10 (CoQ10), referred to as ubiquinol in its
most active (95%) and reduced form (Q10H2), is a lipophilic
molecule present in the membranes of almost all human tissues,
and essential for the respiratory transport chain (Onur et al.,
2014). The side chain serves to keep the molecule anchored
in the inner mitochondrial membrane, and the quinone ring,
which is easily and reversibly reduced to the quinol form,
enables it to fulfill its function of transferring electrons from
complexes I and II to complex III in the respiratory chain,
ultimately resulting in the reduction of oxygen to water and
the generation of ATP (Nowicka and Kruk, 2010; Laredj et al.,
2014). CoQ10 is also capable of recycling and regenerating
other antioxidants such as α-tocopherol and ascorbate. CoQ10
has also been identified as a modulator of gene expression,
inflammatory processes and apoptosis (Bhagavan and Chopra,
2007). The quinol prevents lipid peroxidation by inhibiting the
initial formation and propagation of lipid peroxy radicals, and in
the process it is oxidized to the quinone and H2O2 is produced.
In addition, it has been shown to protect proteins from oxidation
by a similar mechanism (Forsmark-Andrée et al., 1995), and to
prevent oxidative DNA damage such as strand breakages. As
well as its role in the cellular membranes, CoQ is also believed
to function in the blood to protect lipoproteins such as very
low density (VLDL), low density (LDL) and high density (HDL)
lipoproteins from oxidation (Bentinger et al., 2007). Current
evidence suggests that CoQ has a number of independent anti-
inflammatory effects (Schmelzer et al., 2007). It has been shown to
reduce the secretion of pro-inflammatory cytokines in monocytes
and lymphocytes after an inflammatory stimulus by influencing
the expression of NF-κB-dependent genes (Schmelzer et al., 2009;
Bentinger et al., 2010). Furthermore, dietary supplementation
with CoQ10 has been reported to improve ED in patients
with diabetes by up-regulating nitric oxide production (patients
received 200 mg CoQ10/day for 12 weeks) (Watts et al., 2002),
and to decrease hepatic inflammatory stress caused by obesity in
mice (Sohet et al., 2009).
Coenzyme Q10 supplementation at 300 mg/day was reported
to significantly enhance antioxidant enzymes activities and lower
inflammation in patients who have CAD during therapy with
statins (Lee et al., 2013). Statins can effectively lower CoQ
synthesis as they inhibit 3-hydroxy-3-methylglutaryl Coenzyme
A reductase (HMG-CoA reductase), the rate-limiting enzyme
in the pathway of cholesterol synthesis which includes the
formation of the isoprenoid units required to produce CoQ
(Goldstein and Brown, 1990). Moreover, CoQ levels may be
pathologically modified in conditions associated with oxidative
stress and in aging (Potgieter et al., 2013; Botham et al.,
2015).
Data presented in literature on CoQ10 supplementation are
heterogeneous and involve a very large number of pathologies. As
for HF, no conclusions can be drawn on the benefits or harms of
coenzyme Q10 as trials published in literature lack fundamental
information concerning clinically relevant endpoints (Madmani
et al., 2014). More in detail, reports on the effect of CoQ10
in diseases depending on oxidative stress in elderly people are
scarce. In a recent study (Bloomer et al., 2012), 15 exercise-
trained individuals (10 men and 5 women; 30–65 years) received
300 mg of reduced CoQ10 per day or a placebo for 4 weeks in
a random order, double blind, crossover design. Treatment with
CoQ10 resulted in a significant increase in total blood CoQ10
and reduced blood CoQ10, but did not translate into improved
exercise performance or decreased oxidative stress (Bloomer
et al., 2012).
HORMESIS AND GENETIC VARIABILITY
INFLUENCE ON THE OUTCOMES OF
ANTIOXIDANTS SUPPLEMENTATION
As previously reported, clinical trials involving the use of
antioxidants supplementation often show conflicting results and
lead to dangerous misconceptions, either too positive or too
negative, on the use of these molecules in the treatment of
several aging-associated diseases. Amid this debate, the first
aspect that should be considered is that there are several
limitations concerning FRTA, the basic hypothesis on which the
antioxidants supplementation therapies are mainly based. This
theory, as already underlined, suggests a linear dose-response
relationship between increasing amounts of ROS and biological
damages, which potentially culminates in diseases and mortality.
Therefore, oxidative stress should represent the main driving
force of aging and a major determinant of lifespan (Sadowska-
Bartosz and Bartosz, 2014). To date, many investigations have
urged to reexamine FRTA leading to a modernized view of this
theory that takes also in account the so-called “mitohormesis.”
According to this concept, a large amount of ROS causes
detrimental effects on the cells, whereas low or moderate levels
of ROS may exert an opposite effect improving biological
outcomes (Ristow and Schmeisser, 2014; Yun and Finkel, 2014).
The beneficial effects of caloric restriction (CR) and ET are a
good example because they can be considered both as oxidative
stressors or inducer of the endogenous antioxidant system
activation by favoring a transient cellular increase of ROS
(Corbi et al., 2012). Many independent investigations raised
the possibility that an initial induction of ROS triggered by
CR promotes an adaptive stimulation of antioxidant enzymes
at the steady state, consequentially CR is now considered as
the first example of mitohormesis (Agarwal et al., 2005; Schulz
et al., 2007; Mesquita et al., 2010; Zarse et al., 2012). CR
likely induces an adaptive hormetic response through different
molecular pathways, one of these involving sirtuins, a family
of NAD+-dependent deacetylases conserved from yeasts to
humans (Banerjee et al., 2012). SIRT1, the first member of
sirtuins characterized in humans, plays a crucial role in inducing
mitochondrial biogenesis and mediating oxidative stress response
through a number of proteins that promote the expression
of antioxidant genes, such as peroxisome proliferator-activated
receptor (PPAR) gamma coactivator-1 alpha 5 (PGC-1α) (St-
Pierre et al., 2006) and Forkhead transcription factors member,
FOXO3a. SIRT1 interacts with FOXO3a in cells in response to
oxidative stress increasing FOXO3 ability to induce cell cycle
arrest and resistance to oxidative stress and, at the same time
inhibiting FOXO3 ability to induce cell death (Brunet et al.,
2004). Ferrara et al. (2008) demonstrated that exercise-induced
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increase in SIRT1 activity in the heart of aged rats caused an
increase in the expression of FOXO3a and an up-regulation
of FOXO3a targets involved in the oxidative stress response,
including SOD and catalase.
Exercise training, as CR, is to date considered an intervention
triggering a cellular hormetic adaptation (Radak et al., 2005;
Ji et al., 2006). Physical inactivity is indeed one of the major
risk factors for CVD, neurodegenerative disorders and many
other diseases; consequentially, regular physical exercise exerts
health promoting effect on such clinical conditions and in general
on aging-related diseases (Hu et al., 2001; Conti et al., 2012b;
Brown et al., 2013). Exercise is strictly correlated to enhanced
mitochondrial biogenesis and increased production of ROS and
may promote longevity through pathways common to those of
CR (Lanza et al., 2008). However, the benefits linked to ET
strictly depend on the type and workload of exercise and, in
particular, overtraining can result in maladaptation and possibly
cellular damage (Alessio and Goldfarb, 1988; Chevion et al.,
2003; Conti et al., 2012a, 2013). ET has been reported to activate
PGC-1α, which controls mitochondrial gene expression by a
variety of transcription factors (Nikolaidis and Jamurtas, 2009).
This regulation culminates in enhanced oxygen consumption
in muscle fibers, which, in turn, promotes ROS generation.
Moreover, beyond skeletal muscle, other tissues, such as blood,
heart and lung, represent a source of ROS during exercise
(Nikolaidis and Jamurtas, 2009). Concomitantly to enhanced
ROS production, regular exercise leads to the up-regulation
of several antioxidant enzymes, including SODs, catalase and
glutathione peroxidase, reinforcing the concept that a certain
amount of ROS is necessary for exercise health-promoting effects
(Nikolaidis and Jamurtas, 2009).
It is not surprising, then, that both older and recent studies
showed that purified antioxidants supplementation might be
inadequate or even damaging for athletes, as they seem to
abolish ET benefits, including prevention of certain diseases.
A very interesting study by Ristow et al. (2009) investigated
whether exercise could promote insulin-sensitizing abilities in
a ROS-dependent manner in healthy humans. The authors
measured insulin sensitivity by glucose infusion rate (GIR)
and the amount of ROS within skeletal muscle of trained
subjects (previously untrained) in the presence or absence of
antioxidant supplementation with vitamin E and vitamin C. As
expected, ET induced ROS formation, which was counteracted
by the antioxidant treatment. However, concomitantly to the
increase of TBARs, ET was able to stimulate the expression of
antioxidant molecules, such as SOD and GPx and induced an
increase of GIR; these effects were also inhibited by antioxidants
supplementation. The conclusion of this study was that a
transient increase of oxidative stress may contribute to prevent
insulin resistance and type 2 diabetes and, most importantly,
antioxidant supplementation may abrogate these results (Ristow
et al., 2009).
In addition to hormesis another aspect that should be
considered for the conflicting results obtained in the clinical
trials is the genetic background of the patients enrolled in the
studies. In the last decade an increasing number of studies have
suggested that longevity depends not only on life style habits
but also on the genetic background. Oxidative stress response
is one of the most evolutionary conserved pathways involved
in determination of lifespan from yeast to humans (Vijg and
Suh, 2005; vB Hjelmborg et al., 2006) and, indeed, genome wide
association studies (GWAS) have identified genetic determinants
associated to the levels of circulating antioxidants, which could
be linked to human diseases (Ahn et al., 2010). A GWAS
authored by Major et al. (2012) revealed that three single
nucleotide polymorphisms (SNPs), two located in genes involved
in vitamin E transport and metabolism (BUD13 and CYP4F2),
and one in NKAIN3, the gene encoding a Na+/K+ transport
membrane protein, are associated with response to vitamin E
supplementation in humans. The authors concluded that genetic
variation contributes to the variability of serologic vitamin E
status and may have potential application in determining the
regimen of antioxidant supplementation required in complex
diseases such as CVD and diabetes (Major et al., 2012). Very
interesting data concern Haptoglobin (Hp), a protein encoded
by a polymorphic gene with 2 common alleles denoted 1 and 2,
which counteracts the increase of ROS induced by hemoglobin
activity (Sadrzadeh et al., 1984). As previously reported, the
HOPE trial, which investigated the potential protective effect
of vitamin E in cardiovascular patients, showed that treatment
with vitamin E had no effect on cardiovascular outcomes in
patients at high risk for cardiovascular events (Yusuf et al., 2000).
Later, Milman et al. (2008) verified such results moving from
the hypothesis that HOPE study failed to prove the benefit of
vitamin E supplementation because of the inadequate selection of
patient genotype. To this end, the authors planned a prospective
double-blinded clinical trial in a subgroup of individuals from
the HOPE study with type 2 diabetes and found that vitamin
E supplementation was effectively able to reduce cardiovascular
events in patients with the Hp 2-2 genotype (Milman et al.,
2008). Other studies confirmed the impact of Hp genotyping
in determining potential benefits from antioxidant therapy, and
strongly supported the efficacy of a pharmacogenomic strategy
to personalize and fine-tune the treatment with vitamin E in
patients with type 2 diabetes (Blum et al., 2010).
CONCLUSION
Redox state homeostasis in living systems is very complex and
life style factors undeniably concur in determining the impact
of changes in oxidative stress response in both unhealthy and
healthy subjects.
A large part of studies investigating the effectiveness
of antioxidant supplementation therapy in humans raised
contrasting results. This is due to many aspects among which the
often-limited statistic power of the studies, the patient genetic
background, the bioavailability of the molecules used, and the
non-specific effects that antioxidants might have in the human
body, should be taken into account.
Mainly in the elderly, the clinical trials conducted so far often
suffer from an incorrect initial selection of the patients. Further
investigations should be planned to improve patients selection
by performing, for example, quantitative characterizations of the
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redox state for each individual and taking into account both the
individual patient demand and genetic background.
In addition it is worth to underline that, when dealing with
either natural or synthetic antioxidants, clinical trials should
consider other two important aspects. First, antioxidants bearing
different functional moieties can be profoundly diverse in terms
of chemical structure and mode of action; therefore, it should be
recommended to identify the right antioxidant to treat a specific
pathological condition (Bast and Haenen, 2013). Secondly, the
validity of the biomarkers used to determine the effects of
antioxidants on human health are still under debate (van Ommen
et al., 2009). Antioxidants, in fact, might be responsible of subtle
effects specific for human health optimization and/or disease
prevention, which are processes that can be very different in many
aspects from disease onset and progression.
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